![]() ![]() We can bring our AI expertise to your enterprise to save costs and increase operational efficiency. We have red-teaming capabilities for testing new AI technologies. He has leadership experience in various positions at Wyeth Ayerst Pharmaceuticals, Eli Lilly and Company, Amgen Inc. He has over 20 years of diverse pharmaceutical leadership experience. We work with CROs-modeling in vivo animal data, make predictions with target models and predict ADME data to advance their internal drug discovery efforts. Riga was named Spectrum’s President and Chief Executive Officer on January 1st, 2022. BOSTON, March 17, 2023-Spectrum Pharmaceuticals, Inc. We do fee-for-service contract work using our machine learning tools, like endocrine disruption models for global consumer product companies, and ADME models for a large rare disease company. This compares to loss of 0.09 per share a year ago. Spectrum Pharmaceuticals (SPPI) came out with a quarterly loss of 0.02 per share versus the Zacks Consensus Estimate of a loss of 0.05. We have developed collections of models (ADME/toxicity, transporters, kinases etc.) for application to pharmaceutical and consumer product company needs. Spectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue Estimates. We have curated and built thousands of models which we can rapidly apply to clients’ projects. We have developed software that has significantly cut the time required for data curation from poorly curated databases so we can rapidly develop models. Spectrum Pharmaceuticals Inc., whose market valuation is 248. For more than 13 years, Al Mutawwaj Veterinary Pharmaceutical Industries has been offering the local and regional markets its first line of products Spectra. We have decades of drug discovery expertise which we use alongside our machine learning technologies. We are not VC or Angel funded so we do not have others telling us what to work on. What Differentiates Us from Other Companies? We use real drug discovery intelligence alongside artificial intelligence to develop clinical candidates for rare, neglected and unmet therapeutic needs. In the process of our work we have raised awareness of the potential for dual use of these technologies and therefore have expertise for such evaluations which has caught the attention of government agencies. We have also developed new approaches which can be used to rapidly predict molecular properties for massive DNA-encoded libraries or predict properties for PROTACS. We apply our machine learning and drug discovery expertise to a wide array of projects both internally and with collaborators. This is just a brief summary of some of the software products we have generated. UV-adVISor is our new machine learning approach to predict UV-VIS spectra for molecules. ![]() MegaSyn is our latest tool to enable de novo design of molecules. MegaTox®, MegaTrans® and MegaPredict® are core collections of machine learning models that can be used to predict molecular properties and bioactivities that could help in your projects. Assay Central® is one of our machine learning platforms used to create and build our drug pipeline. ![]()
0 Comments
Leave a Reply. |